Remedium Life, a company in the Trading & Distributors industry, reported revenue of ₹111 crore and net profit of ₹8.62 crore for the September 2025 quarter.
Remedium Life (BSE: SUPHA) closed at ₹0.25 on 20 Nov 2026, down 80.9% over the past year. Its market capitalisation is ₹22 crore and it trades at 10.4 times earnings.
Supha Pharmachem Ltd, formerly Remedium Lifecare, is a pharmaceutical supply-chain trader of APIs, advanced intermediates, KSMs/CRMs and other pharma chemicals for domestic and export markets. It operates through the Indian parent and Singapore subsidiary Remlife Global Pte Ltd and entered CIRP on March 17, 2026.
Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.